The purpose of the study is to see how this treatment affects the cancer at the biological level. The study will give the medicines over repeated treatment cycles and follow how the cancer and body change over time. Samples and scans may be collected during the study to learn more about the cancer, and the treatment will be watched for side effects and other safety issues.

Prifetrastat (PF-07248144) is a new medicine that blocks a protein called KAT6, which may help slow cancer growth. ctDNA is small pieces of cancer-related DNA found in the blood, and the study will look at changes in this material to better understand the treatment’s effect. The study also includes analysis of cancer tissue and blood to learn more about how the medicines work.

The study is divided into two phases. In the first phase, the focus is on determining the appropriate dose of Elacestrant when combined with Abemaciclib. In the second phase, the study aims to evaluate how effective this combination is in treating patients with brain metastases from this type of breast cancer. Participants will take the medications orally, and the study will monitor their response to the treatment over time.

Throughout the study, participants will be observed for any changes in their condition, including the size and number of brain metastases. The study will also track any side effects or adverse reactions to the medications. The goal is to gather information that could help improve treatment options for patients with this type of breast cancer in the future.

The purpose of the study is to find out if giving melphalan through the special liver delivery system followed by treatment with one of the other medications works better than giving one of those other medications alone in controlling the cancer in the liver. The study will compare how long patients go without their liver cancer getting worse when they receive the combination treatment versus when they receive only one of the single medications. The study will also look at other measures such as how long patients live, how many patients see their tumors shrink, and how long the response to treatment lasts.

Patients in this study will be randomly assigned to one of two treatment groups. One group will first receive melphalan treatment directed to the liver, followed by treatment with either eribulin, vinorelbine, or capecitabine chosen by their doctor. The other group will receive only one of these three medications without the melphalan treatment first. Patients will be monitored with scans such as computed tomography and magnetic resonance imaging to check how the cancer is responding to treatment. The study will follow patients for up to two years of treatment and will continue to track their health outcomes over time.

The purpose of this study is to find out if GDC-4198 is safe when given alone or together with giredestrant, and to compare how well GDC-4198 combined with giredestrant works against cancer compared to abemaciclib combined with giredestrant. The study will also look at how the body processes these medicines and how they affect the cancer. The study is divided into two stages. In the first stage, a small number of participants will receive GDC-4198 either alone or with giredestrant to check for safety and to understand how the body handles the medicine. In the second stage, a larger number of participants will be randomly assigned to receive either one of two different doses of GDC-4198 combined with giredestrant, or abemaciclib combined with giredestrant. Throughout the study, doctors will monitor participants closely with regular check-ups, blood tests, and scans to see how the cancer responds to treatment and to watch for any side effects.

During the study, doctors will measure several things to understand how well the treatments work and how safe they are. They will check how long it takes before the cancer starts growing again, whether the cancer shrinks or disappears, and how long any improvement lasts. They will also track any unwanted effects from the medicines, changes in vital signs like blood pressure and heart rate, and results from blood tests. The study will also measure the levels of the medicines in the blood at different times to understand how the body processes them. Some participants will receive GDC-4198 with and without food to see if eating affects how the medicine works. The study will continue for several years to gather enough information about the long-term effects of these treatments.

The purpose of this study is to see how well Disitamab Vedotin works against advanced breast cancer in different groups of patients based on their HER2 and hormone receptor levels, particularly in patients who have already received other HER2-targeted treatments like trastuzumab deruxtecan. The study will look at several groups including patients with HER2-positive breast cancer, patients with hormone receptor-positive and HER2-low breast cancer, patients with hormone receptor-positive and HER2-ultralow breast cancer, and patients with hormone receptor-negative and HER2-low breast cancer, which is also called triple-negative breast cancer.

During the study, patients will receive Disitamab Vedotin and doctors will monitor how the cancer responds to the treatment by checking if tumors shrink or stop growing. The study will also track how long any positive responses last, how long patients live without their cancer getting worse, and overall survival. Blood samples will be taken to measure how the medication moves through the body and whether the immune system develops a response to the medication. Doctors will carefully watch for any side effects and will record any health problems that occur during treatment, including whether any changes need to be made to the treatment plan because of these side effects.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The purpose of this research is to evaluate how well the combination of elacestrant and exemestane works in treating this specific type of breast cancer. The study will include patients whose cancer has previously been treated with other therapies but has continued to grow or spread. During the study, patients will receive both medications and undergo various medical examinations to monitor their health and the effectiveness of the treatment.

This is a phase 2 clinical trial, which means it aims to gather more information about how well this combination treatment works. The treatment period may last up to 6 months, during which patients will take their medications daily. Throughout the study, doctors will closely monitor patients’ health and any side effects that may occur.

The purpose of the study is to find out whether adding Inavolisib to the standard injection improves the time that cancer does not get worse, known as progression‑free survival. Participants who have already completed an initial course of treatment are randomly assigned, without knowing which group they are in, to continue receiving either the new pill plus the injection or the placebo pill plus the injection. Treatment is given regularly over several months, and doctors will monitor the participants with routine health checks, scans, and blood tests to see how the cancer behaves and to record any side effects. The study also looks at overall survival, how well the tumor responds, and quality of life during the treatment period.

Several different medications may be used during the study depending on the results of the blood tests. These include fulvestrant, trastuzumab deruxtecan, capecitabine, capivasertib, and elacestrant. Some of these medications are taken as tablets, while others are given as an intravenous infusion, which is medicine delivered directly into a vein, or as an intramuscular injection, which is medicine injected into a muscle.

During the study, blood samples will be analyzed to find somatic alterations, which are changes in the DNA of the cancer cells. The study will also monitor CTCs, or circulating tumor cells, which are cancer cells that have broken away from a tumor and are traveling through the bloodstream. Participants will receive different treatments based on these findings to see which approach works best for their specific type of cancer.

Participants in the study will take these medications over a period of time to see how they affect the growth of the cancer. The study looks at progression-free survival, which is the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival, which is the total length of time a person remains alive, and how well the tumor responds to the medication. The study also monitors how well the body tolerates the drugs and how they impact daily life through patient questionnaires.

The purpose of this study is to evaluate how well inavolisib works and how safe it is when given at two different dose levels in combination with fulvestrant. The study will look at whether the cancer shrinks or disappears in response to treatment, and will pay special attention to certain side effects that can happen with inavolisib, such as high blood sugar levels, mouth sores, and diarrhea. People in the study will be randomly assigned to receive either a 9 milligram dose or a 6 milligram dose of inavolisib each day, along with fulvestrant. The study is designed for people who have already received treatment with a combination of a type of medication called a cyclin-dependent kinase 4/6 inhibitor and hormone therapy, but whose cancer has continued to grow.

During the study, participants will receive their assigned treatment and will be monitored regularly to see how the cancer responds and to check for any side effects. The study will measure things like how many people have their cancer shrink, how long the cancer stays under control, and how long it takes for the cancer to respond to treatment. Participants will also be asked to report symptoms they experience through questionnaires to help understand how the treatment affects their daily life and well-being. The treatment can continue for up to two years, and the entire study is expected to last until mid-2028.

People taking part in this study will receive evorpacept and trastuzumab through a needle into a vein, along with one of the chemotherapy medicines, which may be given either through a vein or as tablets taken by mouth depending on which one is chosen. The treatments will be given in cycles that last 21 days, and participants will continue to receive treatment as long as it is working and not causing unacceptable side effects. During the study, doctors will regularly check how the cancer is responding to treatment using imaging scans, and they will monitor for any side effects or problems that may occur. Blood samples will be taken to measure the levels of the study medicines in the body and to check for any immune reactions to evorpacept.

The study will measure how many people have their tumors shrink or disappear completely with this treatment combination, and how long the treatment keeps working before the cancer starts growing again. Doctors will also track how long people live overall and will carefully record any side effects that occur, including their type and severity. The study will collect information about how the body processes evorpacept and whether the immune system develops antibodies against it.

The purpose of this study is to see how well Datopotamab deruxtecan works in stopping the cancer from getting worse, which is measured by looking at how long patients live without their cancer progressing. The study will also look at how safe the medication is by checking for side effects such as mouth sores, eye problems, and other serious reactions. Patients in this study will receive the study medication and will be monitored regularly to see how their cancer responds to treatment and to check for any side effects. The study will also measure how many patients have their cancer shrink or stay the same size, how long any positive response to treatment lasts, and how long patients survive after starting the treatment.

During the study, doctors will take images and samples to track how the cancer is responding to the medication. The study is designed for patients whose cancer has a specific pattern of hormone receptors and HER2 levels, and who are not suitable candidates for another similar medication. Patients will need to have a certain level of general health and organ function to participate, and their cancer must be measurable or visible on scans. The study will continue for several years to collect information about how well the treatment works over time.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The study aims to understand how a person’s body weight and size affect the way the medication works and what side effects it might cause. The medication will be given in treatment cycles, and researchers will measure the amount of medicine in the blood during the first three cycles of treatment.

During the study, patients will receive T-DXd through an infusion into their vein. Some patients may also receive another medication called pertuzumab along with their treatment. The study will last for up to 24 months, during which time patients will have regular check-ups to monitor their health and how well the treatment is working.

The purpose of this study is to provide continued access to ribociclib treatment for patients who have been receiving this medication in previous Novartis-sponsored studies and have shown benefit from the treatment. The study will monitor how well patients tolerate the treatment over an extended period and track any side effects that may occur.

During the study, patients will continue their current treatment combination that includes ribociclib. The medications are given by mouth as tablets or capsules, except for goserelin acetate which is given as an implant. Patients will have regular check-ups to monitor their health and any potential side effects throughout their participation in the study.

The study aims to test how well patients respond to these treatments and determine the safest and most effective doses. The main treatment being studied is a radioactive drug called [177Lu]Lu-FAP-2286, which will be given either alone or in combination with other cancer medications. This drug works by targeting specific proteins found in cancer cells.

During the study, patients will receive their assigned treatments through intravenous infusion, which means the medications are given directly into a vein. Doctors will monitor patients’ responses to treatment and track any side effects that may occur. The study includes different treatment groups depending on the type of cancer and previous treatments patients have received.

The study will test a combination of two medications: tucatinib (taken as tablets by mouth) and trastuzumab (given through an intravenous infusion into a vein). The purpose is to show that genetic changes in the HER3 protein can be effectively targeted with this treatment combination in breast cancer patients.

During the study, participants will receive treatment for up to 18 months. Before starting treatment, doctors will test tumor tissue samples to confirm the presence of specific genetic changes. Throughout the treatment period, patients will undergo regular health checks and complete quality of life questionnaires. The study will measure how well the tumor responds to treatment and monitor any side effects that may occur.

The study involves several medications that target HER2-positive breast cancer. Patients will receive trastuzumab emtansine (also known as T-DM1) as treatment. Before starting treatment, patients will undergo imaging with a specially modified version of trastuzumab that has been labeled with a radioactive substance to help create detailed images of the cancer. This imaging helps doctors understand how the cancer might respond to treatment.

During the study, patients will receive regular medical check-ups to monitor their response to treatment. The research team will track how long the treatment remains effective and watch for any side effects. They will also collect tissue and blood samples to study how the cancer cells change over time. This information will help doctors better understand which patients are most likely to benefit from specific treatments.

Participants in the study will receive the treatment and be monitored over a period of time to observe any changes in their condition. The study aims to measure the response of the cancer to the treatment, looking for signs of improvement or stability. The treatment will be given in cycles, and the health of the participants will be closely watched by the study team to ensure safety and to gather information on how the treatment affects the cancer.

The study will also collect data on any side effects experienced by participants, as well as other health indicators such as laboratory test results and vital signs. This information will help researchers understand the overall impact of zelenectide pevedotin on patients with NECTIN4 Amplified Advanced Breast Cancer and contribute to the development of new treatment options for this disease.

The purpose of the study is to determine if switching to trastuzumab deruxtecan after a short period of standard treatment can improve the time patients live without the cancer getting worse. Initially, patients will receive standard treatment with a combination of hormone therapy and a type of medication called a CDK4/6 inhibitor. After one month, patients whose blood tests show persistent tumor DNA will switch to the new treatment. The study will monitor how long patients live without the cancer progressing and will also look at overall survival and response to the treatment.

Throughout the study, patients will have regular assessments to check the status of their cancer. These assessments will occur every six weeks during the first year and every nine weeks thereafter. The study will also track any side effects experienced by participants. The goal is to gather information on how well trastuzumab deruxtecan works in this specific group of breast cancer patients and to understand its safety profile.

The purpose of the study is to compare the effectiveness of a new medicine called PF-07220060 when used in combination with another drug called letrozole, against a group of medicines known as CDK4/6 inhibitors (which include abemaciclib, palbociclib, and ribociclib) also used with letrozole. Letrozole is a medication that helps to lower estrogen levels in the body, which can slow the growth of certain types of breast cancer. CDK4/6 inhibitors are a class of drugs that work by interfering with cancer cell division, potentially slowing down or stopping the growth of cancer.

Participants in the study will be randomly assigned to receive either the combination of PF-07220060 and letrozole or one of the CDK4/6 inhibitors with letrozole. The study will last for a period of up to 36 months, during which the progress of the disease will be closely monitored. The main goal is to see which treatment combination is more effective in delaying the progression of the cancer. This study is open to individuals over the age of 18 who have not received any prior systemic treatment for their advanced or metastatic breast cancer.

The purpose of this study is to determine how effective nivolumab is after patients with metastatic TNBC receive one of four different initial treatments. These initial treatments include radiation therapy and three chemotherapy drugs: doxorubicin, cyclophosphamide, and cisplatin. The idea is that these initial treatments might help the immune system respond better to nivolumab.

Participants in the study will first receive one of the initial treatments to potentially boost their immune response. After this, they will receive nivolumab. The study will monitor how the cancer responds to the treatment and how long patients live without the cancer getting worse. The study will also look at the overall survival of patients and any side effects they experience. The trial is expected to continue until June 2026.

The purpose of this study is to explore how well nivolumab works after different treatments that aim to boost the immune system’s response in patients with TNBC that has spread to other parts of the body, known as metastatic disease. Participants in the study will receive nivolumab after undergoing these immune-inducing treatments. The study will monitor how the cancer responds to the treatment and how long patients remain free from cancer progression. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of nivolumab.

Throughout the study, patients will receive regular infusions of nivolumab and will be closely monitored for any changes in their condition. The study will assess various outcomes, including how long patients live without their cancer getting worse and any side effects they may experience. The trial aims to provide valuable information on the effectiveness of nivolumab in treating TNBC and potentially improve treatment strategies for this challenging type of breast cancer.

The purpose of the study is to evaluate if there are differences in the occurrence of high blood sugar levels, known as hyperglycemia, when alpelisib is taken at night with a fasting period and a low carbohydrate diet, compared to taking it as usually recommended. The study will observe participants over a period of three months or until 30 days after they stop the treatment. Participants will be men and postmenopausal women who have a mutation in the PIK3CA gene and have experienced progression of their cancer after previous hormone therapy.

During the study, participants will be randomly assigned to different groups to receive the treatment at different times and under different dietary conditions. The study will monitor the incidence of severe hyperglycemia and other related outcomes. The goal is to determine the best way to administer alpelisib to minimize side effects and improve its effectiveness in treating this type of breast cancer.

The study uses several medications that target HER2-positive breast cancer. The main treatment being studied is trastuzumab emtansine (also known as T-DM1), which is given through an infusion into a vein. This medication combines two parts – one that targets cancer cells and another that helps destroy them. Another medication used in the study is Herceptin, which is also given through an infusion.

The purpose is to understand how cancer cells change after previous treatments and to see how well T-DM1 works in patients whose special scans show certain results. The study involves getting scans, blood tests, and tissue samples to examine the cancer in detail. Patients will receive treatment and be monitored to see how their cancer responds to the medication.

The trial is testing a combination of two treatments: pembrolizumab and olaparib. Pembrolizumab is a type of medicine called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells. Olaparib is a PARP inhibitor, which helps prevent cancer cells from repairing themselves, leading to their death. The purpose of the study is to see how effective this combination is in treating the cancer. Participants will receive these treatments over a period of 27 weeks, and their response to the treatment will be monitored.

Throughout the study, researchers will observe how well the cancer responds to the treatment, how long the response lasts, and how long patients live without the cancer getting worse. They will also monitor any side effects or serious health issues that may occur. This information will help determine if the combination of pembrolizumab and olaparib is a beneficial treatment option for patients with this specific type of breast cancer.

The main purpose of the study is to determine which combination of treatments works best for different groups of patients based on specific characteristics of their cancer, particularly something called the BRCA1-like status. The study will also look at how well the treatments work when combined with atezolizumab, a type of immunotherapy that helps the body’s immune system attack cancer cells.

During the study, patients will receive their assigned treatment through an intravenous infusion. The medications will be given in different combinations, and doctors will monitor how well the treatments work in stopping or slowing down the growth of cancer. They will also track how long patients live without their cancer getting worse and examine various biological markers that might help predict which patients will respond best to specific treatments.

The purpose of the study is to compare the new treatment combination to other therapies chosen by the study doctors. Participants will be randomly assigned to receive either the new treatment or one of the other therapies. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of their cancer. The study aims to see if the new treatment can help delay the progression of the disease.

Participants in the study will include adults over the age of 18 who have previously been treated with a type of medication known as a CDK 4/6 inhibitor, which is used to slow down the growth of cancer cells. The study will also look at how the new treatment affects overall survival, the response of the cancer to treatment, and the quality of life of participants. This research is important for finding new ways to manage and treat advanced breast cancer, offering hope for improved outcomes for patients in the future.

The purpose of the study is to evaluate the safety and tolerability of the combination of ARV-471 and Everolimus. Participants in the study will receive these medications in the form of tablets that are taken orally. The study will monitor participants for any side effects and determine the best dose of the combination treatment. The trial will also look at how the cancer responds to the treatment over time.

Participants will be closely monitored throughout the study to ensure their safety and to gather information on how the treatment affects their cancer. The study aims to find out if this combination of medications can be a safe and effective treatment option for people with ER-positive, HER2-negative advanced or metastatic breast cancer. The trial is expected to continue until 2025, with the goal of providing valuable insights into this potential treatment option.

The purpose of the study is to see if the combination of TUKYSA and Kadcyla can help patients live longer without their cancer getting worse. Participants in the study will be randomly assigned to receive either the combination of TUKYSA and Kadcyla or Kadcyla with a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results. The study will last for a period of time, during which participants will receive regular treatments and have their health monitored closely by the research team.

Throughout the study, participants will undergo various assessments to track the progress of their cancer. These assessments may include imaging tests like MRI (magnetic resonance imaging) to check for any changes in the cancer, especially in the brain if there are concerns about cancer spreading there. The main goal is to compare how long patients can live without their cancer worsening, using a standard set of criteria known as RECIST (Response Evaluation Criteria in Solid Tumors). The study will also look at other outcomes, such as overall survival and response rates to the treatment.

The purpose of the study is to find the best dose of BB-1701 and to see how safe and effective it is for people who have already received treatment for their cancer. The study will be conducted in two parts. In the first part, different doses of BB-1701 will be tested to find the most suitable one. In the second part, the chosen dose will be given to more participants to further evaluate its effects. Participants will receive the treatment through an infusion, which means the medication will be given directly into a vein.

Throughout the study, the safety of BB-1701 will be closely monitored by checking for any side effects and conducting regular health assessments. The effectiveness of the treatment will be evaluated by observing how the cancer responds to the medication. This includes looking at whether the cancer shrinks or stops growing. The study aims to provide valuable information about the potential benefits of BB-1701 for treating HER2-positive or HER2-low metastatic breast cancer.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

The purpose of the study is to evaluate the safety and effectiveness of using abemaciclib in combination with tamoxifen, or using abemaciclib alone, in women who have previously been treated for hormone receptor-positive and HER2-negative metastatic breast cancer. Hormone receptor-positive means that the cancer cells grow in response to hormones, and HER2-negative indicates that the cancer does not have high levels of the protein HER2, which can promote the growth of cancer cells.

Participants in the study will receive either the combination of abemaciclib and tamoxifen or abemaciclib alone. The study will monitor the participants over a period to assess how the cancer responds to the treatment and to observe any side effects. The goal is to determine how long the treatment can prevent the cancer from progressing and to measure the overall response to the treatment. The study aims to provide valuable information that could help improve treatment options for women with this type of breast cancer.

The purpose of the study is to see if supervised group exercise, which includes aerobic and resistance training, can improve the effectiveness of cancer treatment. Additionally, the study will investigate whether combining this exercise with atorvastatin can further enhance the response to cancer therapy. Participants will be divided into groups, with some receiving supervised exercise sessions and others managing their own exercise routines. Some participants will also take atorvastatin, while others may receive a placebo.

The study will take place over a period of time, with participants being monitored for changes in their cancer’s progression and overall health. The goal is to determine if these interventions can help slow down the cancer or improve survival rates. This research could provide valuable insights into new ways to support cancer treatment through lifestyle changes and medication.

Participants in the study will receive the treatment and be monitored to see how their cancer responds. The study will look at the percentage of patients whose cancer shrinks or disappears after treatment, as well as those whose disease remains stable. The trial will also assess how long it takes for the cancer to progress and the overall survival of the participants. Additionally, the study will monitor the levels of disulfiram in the blood to understand how the body processes the drug and will keep track of any side effects experienced by the participants.

The trial is designed to provide valuable information about the potential benefits and safety of using disulfiram with copper for treating metastatic breast cancer. Participants will take the medication orally, and the study will continue for a period of time to gather comprehensive data on the treatment’s impact. The findings from this trial could contribute to developing new treatment options for individuals with this type of cancer.

The purpose of the study is to find a suitable dose of JZP598 when used with palbociclib and fulvestrant and to assess the combination’s ability to control the cancer. The study is divided into two parts. In the first part, researchers will determine the best dose of JZP598 to use with the other medications. In the second part, they will evaluate how well this combination works in treating the cancer. Participants will receive the medications through different methods: JZP598 is given as an infusion, palbociclib is taken orally as a capsule, and fulvestrant is administered as an injection.

Throughout the study, participants will be monitored for any side effects and how their cancer responds to the treatment. The study aims to provide valuable information on the effectiveness and safety of using these medications together for treating HER2-positive, HR-positive breast cancer. The trial is expected to continue until early 2026, with the goal of improving treatment options for patients with this type of breast cancer.

The purpose of the study is to determine which treatment is more effective in delaying the progression of the cancer. Participants in the study will be randomly assigned to receive either the hormone therapy with abemaciclib or the chemotherapy. The study will monitor the participants over a period to see how long the cancer can be controlled without worsening. The study will also assess the quality of life of the participants during the treatment period using questionnaires.

Throughout the study, participants will receive regular assessments to track the progress of their treatment. These assessments will include medical tests and evaluations to ensure the safety and effectiveness of the treatments. The study will continue until the estimated end date in 2028, with the goal of providing valuable information on the best treatment options for patients with this type of breast cancer.

Participants in the study will receive one of several possible treatments, which include medications such as Palbociclib, Capecitabine, Niraparib, Doxorubicin Hydrochloride, Topotecan, Paclitaxel, Sacituzumab Govitecan, Fulvestrant, Carboplatin, Docetaxel, Vinorelbine, Olaparib, Bevacizumab, Cyclophosphamide, and Etoposide. Some patients may receive a placebo, which is a substance with no active medication. The study will last for a maximum of 24 months, during which the effectiveness of the treatments will be monitored.

The main goal of the study is to see if the zAvatar-test can better predict which treatments will work best for patients, helping to improve their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at other outcomes, such as the overall survival of patients and their response to the treatments. This research could lead to more personalized and effective treatment options for patients with these types of cancer.

The purpose of the study is to compare the effectiveness of these two treatment combinations in patients who have already been treated with another medication called trastuzumab deruxtecan but have not responded well or cannot tolerate it. Participants in the study will receive one of the two treatment combinations, and their progress will be monitored over a period of time. The study will look at how long patients live without the cancer getting worse and other important health outcomes.

During the study, participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study aims to provide valuable information about which treatment combination might be more beneficial for patients with this type of breast cancer. The study is expected to continue for several years to gather enough data to make a clear comparison between the two treatment options.